Post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding

By -

 

Executive Summary

Bleeding is a significant adverse event associated with Endoscopic Retrograde Cholangiopancreatography (ERCP), occurring in approximately <1 to 3 percent of cases. While advancements in equipment and training have reduced the frequency of these events, bleeding—particularly following biliary or pancreatic sphincterotomy—remains a serious clinical concern with a mortality rate of approximately 0.05 percent. Successful management relies on identifying patient- and procedure-related risk factors, implementing rigorous preventive strategies (including the optimization of coagulation and adjustment of antithrombotic medications), and employing a tiered approach to endoscopic hemostasis. Most cases can be managed endoscopically, though refractory bleeding may require interventional radiology or surgical consultation.

Epidemiology and Clinical Definitions

ERCP is primarily a therapeutic procedure used for managing pancreaticobiliary disorders. Because other diagnostic tools like magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound (EUS) are lower risk, ERCP is reserved for interventions where bleeding risk is inherent.

Severity Grading

Professional consensus defines clinically significant post-ERCP bleeding as hematemesis, melena, and/or a drop in hemoglobin exceeding 2 g. The severity is graded based on the clinical impact and resource utilization:

Grade

Clinical Criteria

Mild

Procedure aborted due to bleeding and/or unplanned hospital admission <4 nights.

Moderate

Unplanned admission for 4–10 nights; ICU admission for 1 night; requirement for blood transfusion, repeat endoscopy, or interventional radiology.

Severe

Unplanned admission for >10 nights; ICU admission for >1 night; and/or need for surgical intervention.

Risk Factor Analysis

Risk factors for post-ERCP bleeding are categorized into three primary domains: patient-related, procedure-related, and endoscopist-related.

Patient-Related Factors

  • Hemostatic Disorders: Disorders of hemostasis, including those stemming from cirrhosis, end-stage kidney disease (ESKD), or malnutrition.

  • Pharmacology: Use of anticoagulants or antiplatelet agents (excluding aspirin in some contexts).

  • Clinical Condition: Acute cholangitis or high bilirubin levels (>10 mg/dL).

  • Anatomy: Ampullary tumors, stenosis, surgically altered anatomy (e.g., Billroth II gastrectomy), or impacted gallstones.

Procedure-Related Factors

  • Incision Technique: Skewed direction of sphincterotomy or "zipper cuts" (sudden, uncontrolled papillary incisions).

  • Current Type: Use of pure-cut electrical current rather than blended current.

  • Specific Interventions: Extension of a previous sphincterotomy or endoscopic snare papillectomy.

Endoscopist-Related Factors

  • Experience Level: Endoscopists with limited experience or low case volume (defined as performing \leq 1 ERCP per week) are associated with higher complication rates.

Preventive Strategies

Preventive measures focus on pre-procedural optimization and intra-procedural technique.

Optimization of Coagulation Status

For high-risk procedures like ERCP, clinical thresholds typically require a platelet count >50,000/microL and an INR <1.5.

  • Laboratory Testing: Standard for patients with active bleeding, known hemostatic disorders, use of anticoagulants, chronic cholestasis, or cirrhosis.

  • Antithrombotic Management: Decisions must balance thromboembolic risk against bleeding risk.

    • Antiplatelet agents: P2Y receptor blockers (e.g., clopidogrel) are generally discontinued.

    • Aspirin: Often continued for secondary prevention (history of cardiovascular disease) but may be stopped for 5–7 days if used only for primary prevention.

    • Warfarin: Interrupted to achieve a goal INR <1.5.

    • DOACs: Last dose should be taken >48 hours (rivaroxaban, apixaban, edoxaban) or >72 hours (dabigatran) before the procedure.

Intra-procedural Techniques

  • Sphincterotomy Precision: Positioning the wire between 11 and 1 o'clock and performing a slow, gradual incision.

  • Electrosurgery: Utilizing blended (mixed) current consisting of both cut and coagulation modes is associated with lower bleeding risk compared to pure-cut current.

  • Alternatives: Endoscopic papillary balloon dilation (EPBD) may be used for small stones in patients with hemostatic disorders to reduce bleeding risk, though it carries a higher risk of pancreatitis.

Clinical Presentation and Initial Management

While bleeding can occur immediately, most patients present at least 24 hours post-procedure, primarily with melena.

Resuscitation and Stabilization

Management follows standard upper gastrointestinal (GI) bleeding protocols:

  • Fluid Resuscitation: Initial boluses of isotonic crystalloid.

  • Transfusion Thresholds: Generally targeted at Hemoglobin <7 g/dL, or <8 g/dL in patients with stable coronary artery disease. For those with acute coronary syndrome and ongoing ischemia, the goal may be higher (Hgb <9–10 g/dL).

  • Pharmacotherapy: Pre-endoscopic proton pump inhibitors (e.g., IV Pantoprazole 80 mg).

Endoscopic Hemostasis Methods

Endoscopic evaluation with a side-viewing endoscope should occur within 24 hours of admission. If the source is not found, a forward-viewing scope is used to rule out other GI sources.

First-Line Interventions

  • Epinephrine Injection: Submucosal injection of diluted epinephrine (1:10,000) in aliquots of 0.5 to 1 mL. Critical Note: Endoscopists must avoid the 6 o'clock position (lower border) to prevent trauma to the pancreatic duct orifice and subsequent pancreatitis.

  • Thermal Coagulation: Used for visible vessels or active bleeding via bipolar electrocautery (BICAP), monopolar forceps, or the sphincterotome wire.

  • Endoscopic Clips: Effective for visible vessels, though technically challenging via a duodenoscope. Clips should be placed at the upper border of the sphincterotomy.

Subsequent and Refractory Interventions

  • Fully Covered SEMS: Temporary placement of a fully covered self-expandable metal stent in the bile duct provides mechanical compression. These are typically removed in 4–6 weeks.

  • Hemostatic Sprays/Powders: Used when traditional methods are technically unfeasible due to the lesion's size or position.

  • Balloon Tamponade: Inflation of a stone extraction balloon at the site for 1–2 minutes can provide short-term hemostasis.

  • Angiographic Embolization: Selective arterial supply occlusion by interventional radiology. Effective but carries a risk of bowel wall ischemia.

  • Surgery: Rarely required; options include converting the sphincterotomy to a sutured sphincteroplasty.

Risk of Rebleeding

Approximately 22 percent of patients experience rebleeding after initial successful hemostasis. High-risk indicators for recurrence include:

  • Bilirubin levels >10 mg/dL.

  • Initial severe bleeding (requiring ≥ 5 units of blood or interventional/surgical rescue).